Bernstein keeps Agilon Health at "outperform" and raises price target from $125 to $138
Bernstein kept its "outperform" rating on Agilon Health and raised its price target from $125 to $138, a 10.4% increase. The new target implies 52.4% upside from the November 18 close of $90.53. The three most recent analyst notes on the company over the past 30 days set price targets between $105 and $170.
In 25 seconds
- Bernstein reiterates its "outperform" rating on Agilon Health.
- The price target rises from $125 to $138, 10.4% higher.
- The new target implies 52.4% upside from the November 18 close of $90.53.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.





Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.